Interpretation and Use of Natriuretic Peptides in Non-Congestive Heart Failure Settings

Shih-Hung Tsai,Yen-Yue Lin,Shi-Jye Chu,Ching-Wang Hsu,Shu-Meng Cheng

DOI: https://doi.org/10.3349/ymj.2010.51.2.151

2010-01-01

Yonsei Medical Journal

Abstract:Natriuretic peptides (NPs) have been found to be useful markers in differentiating acute dyspneic patients presenting to the emergency department (ED) and emerged as potent prognostic markers for patients with congestive heart failure (CHF). The best-established and widely used clinical application of BNP and NT-proBNP testing is for the emergent diagnosis of CHF in patients presenting with acute dyspnea. Nevertheless, elevated NPs levels can be found in many circumstances involving left ventricular (LV) dysfunction or hypertrophy; right ventricular (RV) dysfunction secondary to pulmonary diseases; cardiac inflammatory or infectious diseases; endocrinology diseases and high output status without decreased LV ejection fraction. Even in the absence of significant clinical evidence of volume overload or LV dysfunction, markedly elevated NP levels can be found in patients with multiple comorbidities with a certain degree of prognostic value. Potential clinical applications of NPs are expanded accompanied by emerging reports regarding screening the presence of secondary cardiac dysfunction; monitoring the therapeutic responses, risk stratifications and providing prognostic values in many settings. Clinicians need to have expanded knowledge regarding the interpretation of elevated NPs levels and potential clinical applications of NPs. Clinicians should recognize that currently the only reasonable application for routine practice is limited to differentiation of acute dyspnea, rule-out-diagnostic-tests, monitoring of therapeutic responses and prognosis of acute or decompensated CHF. The rationales as well the potential applications of NPs in these settings are discussed in this review article.

medicine, general & internal

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to interpret and use the phenomenon of elevated natriuretic peptide (NPs) levels in a non - congestive heart failure (Non - CHF) environment. Specifically, the paper explores the potential clinical applications of NPs in various non - CHF disease states, including but not limited to acute coronary syndrome, cardiac surgery, pulmonary embolism, pulmonary hypertension, chronic lung disease, valvular heart disease, cardiac arrhythmia, cardiovascular inflammatory or infectious diseases, etc. The paper emphasizes that NPs not only play an important role in the diagnosis of acute dyspnea and acute heart failure, but also discusses their potential in screening for secondary cardiac dysfunction, monitoring treatment responses, and providing prognostic value.

By analyzing the performance of NPs in different disease states, the paper aims to expand clinicians' understanding of the reasons behind elevated NPs levels and guide their rational application in clinical practice. For example, the paper points out that even in the absence of significant clinical evidence of volume overload or left ventricular dysfunction, a significantly elevated NPs level may have certain prognostic value, especially in patients with multiple comorbidities. In addition, the paper also mentions the application of NPs in certain specific diseases, such as for evaluating graft rejection in heart transplant patients and predicting the risk of complications after cardiac surgery.

In summary, the goal of this paper is to provide a comprehensive perspective to help clinicians better understand and utilize the clinical significance and application of NPs in a non - CHF environment.